SOHM, Inc. Shares an Exciting Expansion and Upcoming Presentation on ABBIE
SOHM Inc. (OTC PINK:SHMN) has announced significant developments in its biotechnology operations. The company is expanding its ABBIE genome editing and cell engineering program at their Carlsbad facility and UACI labs to support growing Next-Generation Sequencing (NGS) validation requirements.
The strategic expansion aims to meet increasing demands for engineered mouse models and cell lines important for drug development, gene therapy, and immunotherapy. The company is also enhancing its AI-enabled ABBIE platform for next-generation gene editing applications.
Additionally, SOHM will present a poster titled 'ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration' at the American Society of Gene and Cell Therapy Conference, scheduled for May 13-17 in New Orleans, LA.
SOHM Inc. (OTC PINK:SHMN) ha annunciato sviluppi significativi nelle sue operazioni biotecnologiche. L'azienda sta ampliando il suo programma di editing genomico e ingegneria cellulare ABBIE presso la loro struttura di Carlsbad e i laboratori UACI per supportare i crescenti requisiti di validazione del Next-Generation Sequencing (NGS).
L'espansione strategica mira a soddisfare la crescente domanda di modelli murini ingegnerizzati e linee cellulari importanti per lo sviluppo di farmaci, la terapia genica e l'immunoterapia. L'azienda sta anche migliorando la sua piattaforma ABBIE abilitata all'IA per applicazioni di editing genetico di nuova generazione.
Inoltre, SOHM presenterà un poster intitolato 'Editing Genomico ABBIE: Una Scoperta nell'Integrazione Genomica Precisa, Replicabile e Tracciabile' alla Conferenza della Società Americana di Terapia Genica e Cellulare, in programma dal 13 al 17 maggio a New Orleans, LA.
SOHM Inc. (OTC PINK:SHMN) ha anunciado desarrollos significativos en sus operaciones de biotecnología. La empresa está ampliando su programa de edición del genoma y ingeniería celular ABBIE en su instalación de Carlsbad y laboratorios UACI para apoyar los crecientes requisitos de validación de la Secuenciación de Nueva Generación (NGS).
La expansión estratégica tiene como objetivo satisfacer la creciente demanda de modelos de ratón e líneas celulares diseñadas, importantes para el desarrollo de fármacos, terapia génica e inmunoterapia. La empresa también está mejorando su plataforma ABBIE habilitada por IA para aplicaciones de edición genética de nueva generación.
Además, SOHM presentará un póster titulado 'Edición Genómica ABBIE: Un Avance en la Integración Genómica Precisa, Replicable y Rastreable' en la Conferencia de la Sociedad Americana de Terapia Génica y Celular, programada para el 13 al 17 de mayo en Nueva Orleans, LA.
SOHM Inc. (OTC PINK:SHMN)는 생명공학 운영에서 중요한 발전을 발표했습니다. 이 회사는 카를스바드 시설과 UACI 실험실에서 ABBIE 유전체 편집 및 세포 공학 프로그램을 확장하여 증가하는 차세대 염기서열 분석(NGS) 검증 요구 사항을 지원하고 있습니다.
이 전략적 확장은 의약품 개발, 유전자 치료 및 면역 요법에 중요한 엔지니어링 마우스 모델 및 세포주에 대한 증가하는 수요를 충족하는 것을 목표로 하고 있습니다. 이 회사는 또한 차세대 유전자 편집 응용 프로그램을 위한 AI 지원 ABBIE 플랫폼을 강화하고 있습니다.
또한 SOHM은 5월 13일부터 17일까지 뉴올리언스, LA에서 열리는 미국 유전자 및 세포 치료 학회에서 'ABBIE 유전자 편집: 정밀하고 복제 가능하며 추적 가능한 유전체 통합의 돌파구'라는 제목의 포스터를 발표할 예정입니다.
SOHM Inc. (OTC PINK:SHMN) a annoncé des développements significatifs dans ses opérations biotechnologiques. L'entreprise étend son programme d'édition du génome et d'ingénierie cellulaire ABBIE dans ses installations de Carlsbad et dans les laboratoires UACI pour soutenir les exigences croissantes de validation du séquençage de nouvelle génération (NGS).
Cette expansion stratégique vise à répondre à la demande croissante de modèles murins et de lignées cellulaires conçus, qui sont importants pour le développement de médicaments, la thérapie génique et l'immunothérapie. L'entreprise améliore également sa plateforme ABBIE activée par IA pour les applications d'édition génétique de nouvelle génération.
De plus, SOHM présentera un poster intitulé 'Édition Génomique ABBIE : Une percée dans l'intégration génomique précise, reproductible et traçable' lors de la Conférence de la Société Américaine de Thérapie Génique et Cellulaire, prévue du 13 au 17 mai à La Nouvelle-Orléans, LA.
SOHM Inc. (OTC PINK:SHMN) hat bedeutende Entwicklungen in seinen biotechnologischen Aktivitäten angekündigt. Das Unternehmen erweitert sein ABBIE-Programm zur Genom-Editierung und Zelltechnik an seinem Standort in Carlsbad und den UACI-Labors, um den wachsenden Anforderungen an die Validierung von Next-Generation Sequencing (NGS) gerecht zu werden.
Die strategische Expansion zielt darauf ab, die steigende Nachfrage nach ingenieurtechnisch entwickelten Mausmodellen und Zelllinien zu decken, die für die Arzneimittelentwicklung, Gentherapie und Immuntherapie wichtig sind. Das Unternehmen verbessert auch seine KI-gestützte ABBIE-Plattform für Anwendungen der Genom-Editierung der nächsten Generation.
Darüber hinaus wird SOHM ein Poster mit dem Titel 'ABBIE-Geneneditierung: Ein Durchbruch in der präzisen, reproduzierbaren und nachverfolgbaren genomischen Integration' auf der Konferenz der American Society of Gene and Cell Therapy präsentieren, die vom 13. bis 17. Mai in New Orleans, LA, stattfinden wird.
- None.
- None.
CHINO HILLS, CA / ACCESS Newswire / April 10, 2025 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, is thrilled to announce and share some exciting developments at SOHM Inc.! Our commitment to innovation and excellence continues to drive our growth, and we are delighted to announce the expansion of our ABBIE genome editing and cell engineering program at our Carlsbad facility along with our UACI labs.
This expansion is a strategic move to support our ever-growing Next-Generation Sequencing (NGS) validation needs. With an increasing number of licensing opportunities on the horizon, we are poised to meet the demand for engineered mouse models and cell lines vital for drug development, gene therapy, and immunotherapy. Additionally, this expansion will enhance our AI-enabled ABBIE platform, paving the way for revolutionary applications in next-generation gene editing. Dr. David Aguilar, COO, added.
We are equally excited to inform you that SOHM Inc. will be presenting a poster at the prestigious American Society of Gene and Cell Therapy Conference, taking place from May 13-17 in vibrant New Orleans, LA. Our poster is entitled "ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration," highlighting our cutting-edge advancements in this critical field.
Further details regarding the poster event will be shared in due course, and we look forward to your continued support as we embark on this thrilling journey.
Thank you for being an integral part of SOHM Inc.'s success!
For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com:
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is the purpose of SOHM's (SHMN) ABBIE program expansion at Carlsbad facility?
When and where will SOHM (SHMN) present their ABBIE Gene Editing research?
What are the key applications of SOHM's (SHMN) ABBIE platform?
How is SOHM (SHMN) advancing its gene editing capabilities?
What facilities are involved in SOHM's (SHMN) ABBIE program expansion?
